

**PRESS RELEASE 28<sup>th</sup> Sep 2011: Beremans Ltd announces publication of “UK/Ireland biotechnology sector: clinical phase drug development pipeline”.**

Beremans Ltd ([www.beremans.com](http://www.beremans.com)), the Cambridge (UK)-based provider of business intelligence services for the Life Sciences sector, announced today the publication of a report entitled **‘UK/Ireland biotechnology sector: clinical phase drug development pipeline’**. The report identifies all UK and Irish biotechnology companies with drug candidates that have entered clinical trials. All clinical phase drug candidates being developed by these companies are listed, both by clinical trial phase and by the category of disease (ICD-10) that they are intended to address. A table is provided containing a brief outline of each company (public/private status, geographic location, web address, focus of activity, pipeline summary). The report contains information likely to be of use to, *inter alia*, parties contemplating licensing, merger or acquisition activity in the UK/Irish biotechnology sector, or parties intending to provide specific products or services to companies in this sector.

A free summary of the report is provided at [www.beremans.com](http://www.beremans.com). In brief, the report contains 7 charts and 23 tables, and briefly outlines 157 clinical phase drug programmes under development by 66 biotechnology companies in UK/Ireland. Of these companies, 58 are based in England, 3 in Ireland, 4 in Scotland and 1 in Wales; 27 are public, and 39 are private. Of the 157 drug programmes, 47 are in Phase I, 81 are in Phase II, and 29 are in  $\geq$ Phase III. The majority of drug development activity is applied to three disease categories (see summary for details).

For further information, please email Dr. Nicholas Miller [nm01@beremans.com](mailto:nm01@beremans.com)